ArticleActa neurologica Belgica2026
Long-term clinical course and extracerebellar manifestations of hereditary spinocerebellar degeneration.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHereditary spinocerebellar degeneration (hSCD) comprises a heterogeneous group of inherited neurodegenerative diseases characterized by slowly progressive ataxia and various extracerebellar manifestations. This study aimed to investigate the long-term clinical course of hSCD, including quantitative information on disease progression.
methodsWe enrolled 42 consecutive patients with various hSCD genotypes and followed them for a mean of 9 years. We used the International Cooperative Ataxia Rating Scale (ICARS) to assess ataxia, and we evaluated the extracerebellar manifestations.
resultsThe mean annual increase in the ICARS score was 2.6 ± 5.9 points/year, with no significant differences detected among genotypes in exploratory subgroup comparisons. At baseline, half of the patients had extracerebellar manifestations, including pyramidal signs (31.0%), sensory disturbances (21.4%), and autonomic symptoms (16.7%). The frequency of these manifestations increased with disease progression. The presence of extracerebellar manifestations at baseline was associated with greater increases in the ICARS scores over time and an earlier onset of wheelchair dependence. Brain perfusion analysis revealed that reduced blood flow to the precentral gyrus at baseline was associated with the manifestation of pyramidal signs at the endpoint.
conclusionAs the disease progressed, extracerebellar manifestations gradually appeared. These manifestations may reflect more widespread neurodegeneration and may help identify patients at higher risk of clinical deterioration. Careful assessment and appropriate management of both cerebellar and extracerebellar manifestations may be clinically important for optimizing patient outcomes.
Indexed as
Identifiers
42631841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.